Contribute Try STAT+ Today

I asked a seasoned biotech business development executive, a guy who spends a lot of time digging deep into cancer drugs for potential licensing deals, what he thought about the experimental prostate cancer drug acquired by Endocyte (ECYT). Since announcing the deal on Monday morning, Endocyte’s stock price has quadrupled.

“PSMA is a target proven over and over as ineffective in treating prostate cancer due to significant off-target toxicity. Anyone looking at this can pretty much stop there,” he told me.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • A cure for any cancer would end a lot of business. Nothing to see here folks…but speculate away to only the benefit of the business leaders.

Comments are closed.